(1.28%) 5 074.51 points
(0.75%) 38 528 points
(1.71%) 15 716 points
(1.65%) $83.25
(0.00%) $1.791
(-0.29%) $2 339.70
(0.44%) $27.37
(-1.01%) $921.85
(-0.46%) $0.934
(-0.67%) $10.91
(-0.84%) $0.803
(-0.12%) $93.30
Live Chart Being Loaded With Signals
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...
Stats | |
---|---|
Today's Volume | 5.00 |
Average Volume | 90.00 |
Market Cap | 1.84B |
EPS | $27.56 ( 2023-09-30 ) |
Last Dividend | $0.105 ( 2022-09-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.78 |
ATR14 | $0 (0.00%) |
Nippon Shinyaku Co., Ltd. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nippon Shinyaku Co., Ltd. Financials
Annual | 2023 |
Revenue: | $144.18B |
Gross Profit: | $88.20B (61.17 %) |
EPS: | $338.70 |
Q3 | 2023 |
Revenue: | $39.41B |
Gross Profit: | $26.12B (66.28 %) |
EPS: | $116.20 |
Q2 | 2023 |
Revenue: | $36.30B |
Gross Profit: | $23.94B (65.96 %) |
EPS: | $27.57 |
Q1 | 2023 |
Revenue: | $37.01B |
Gross Profit: | $24.05B (64.98 %) |
EPS: | $32.48 |
Financial Reports:
No articles found.
Nippon Shinyaku Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.105 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0575 | 2017-10-02 |
Last Dividend | $0.105 | 2022-09-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $1.029 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.11 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.36 | |
Div. Directional Score | 10.00 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UNCRY | Ex Dividend Junior | 2023-04-24 | Annually | 0 | 0.00% | |
KSBI | Ex Dividend Knight | 2023-07-28 | Quarterly | 0 | 0.00% | |
CIWV | Ex Dividend Knight | 2023-07-20 | Quarterly | 0 | 0.00% | |
SBNC | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
GBLBY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
ALIZY | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
WTKWY | Ex Dividend Knight | 2023-08-29 | Annually | 0 | 0.00% | |
MOHCY | Ex Dividend Knight | 2023-06-26 | Annually | 0 | 0.00% | |
COIHY | Ex Dividend Knight | 2023-08-31 | Semi-Annually | 0 | 0.00% | |
SRCU | Ex Dividend Junior | 2023-08-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.164 | 1.500 | 6.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0974 | 1.200 | 6.75 | 8.10 | [0 - 0.3] |
returnOnEquityTTM | 0.117 | 1.500 | 9.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.331 | -1.000 | 6.69 | -6.69 | [0 - 1] |
currentRatioTTM | 5.92 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.17 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.11 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00826 | -1.500 | 9.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 264.20 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00953 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.646 | 1.000 | 2.57 | 2.57 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.226 | 1.000 | 7.47 | 7.47 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 10.59 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.593 | 0.800 | 9.38 | 7.50 | [0.5 - 2] |
Total Score | 13.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.29 | 1.000 | 9.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.117 | 2.50 | 9.88 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 163.50 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00894 | 1.500 | 9.78 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 321.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.331 | 1.500 | 6.69 | -6.69 | [0 - 1] |
pegRatioTTM | 0.000772 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.147 | 1.000 | 8.81 | 0 | [0.1 - 0.5] |
Total Score | 6.36 |
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators